MDTMedtronic Plc

ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.

ISRG's strong procedure growth, recurring revenue and cash position support its case, but tariffs, mix shifts and placement risks cloud the outlook.

Medtronic (MDT) reached $82.35 at the closing of the latest trading day, reflecting a -1.13% change compared to its last close.

A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026 A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery Aide, the next-generation compute platform for...

Medtronic to announce financial results for its first quarter of fiscal year 2027 Medtronic to announce financial results for its first quarter of fiscal year 2027 PR Newswire GALWAY, Ireland, July 20, 2026 GALWAY, Ireland, July 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in...

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain PR Newswire GALWAY, Ireland...

Medtronic (MDT) reached $83.87 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.